Last reviewed · How we verify
2x 50 L3 larvae infection — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
2x 50 L3 larvae infection (2x 50 L3 larvae infection) — Leiden University Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 2x 50 L3 larvae infection TARGET | 2x 50 L3 larvae infection | Leiden University Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 2x 50 L3 larvae infection CI watch — RSS
- 2x 50 L3 larvae infection CI watch — Atom
- 2x 50 L3 larvae infection CI watch — JSON
- 2x 50 L3 larvae infection alone — RSS
Cite this brief
Drug Landscape (2026). 2x 50 L3 larvae infection — Competitive Intelligence Brief. https://druglandscape.com/ci/2x-50-l3-larvae-infection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab